Currently, in preclinical studies, pirfenidone and fresolimumab are considered as a potential therapeutic way for renal fibrosis, which is the direct blockade of the TGFβ-Smad2/3 classical signaling pathway with antagonists or inhibitors (Fan et al., 1999; Xavier et al., 2015). This evidence concerns the gene SMAD2 and renal fibrosis.